Subscribe to our blog for updates.
By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
What Investors Are Watching at JPM 2026
Signals That Will Matter Beyond the Conference Each January, the J.P. Morgan Annual Healthcare Conference offers a rare moment of signal clarity. Management teams, investors, strategics, and advisors ...
The Evolution of Healthcare IT: Defining Five Software-Driven Subsegments and What Public Equity Investors are Focused on
Over the past decade, the Healthcare IT sector has evolved into a set of distinct, data-driven markets with separate ecosystems of specialized platforms. From facility operations to clinical research,...
Biotech Playbook: Financing, Dealmaking, and What’s Next Ahead of JPM 2026
As the industry turns its attention toward JPM 2026, conversations across the biotech community are increasingly focused on capital strategy, dealmaking momentum, and how companies can position themse...
Investor Engagement 2.0: Building Momentum Beyond Conferences and Earnings
On October 29th, Gilmartin Group hosted Investor Engagement 2.0: Building Momentum Beyond Conferences and Earnings, a discussion on how management teams can strengthen investor connectivity and visibi...
Non-Deal Roadshow Prep: A Strategic Guide for Management Teams
Non-deal roadshows (NDRs) are a critical part of a company’s investor relations program. At the bare minimum, they allow companies to be visible to investors outside of any interactions at investor ...
Messaging Clinical Data: Building Trust Through Transparent Communication
Communicating clinical data represents important inflection points for development-stage companies, often defining their business strategy and financial trajectories for years to come. Unlike more est...
The New Reality: C-Suite IR Responsibilities Following an IPO
Going public is a milestone—validation of your company’s growth, business model, and future potential. But for executive teams, the IPO isn’t the finish line. In fact, it marks the beginning of ...
Surviving the Squeeze: Creative Capital Raising Strategies for Biotechs in a Risk-Off Market
On June 24th, Gilmartin Group’s Founder, Lynn Lewis, and Principal, Kiki Patel, PharmD moderated a discussion with the Jefferies Investment Banking team including Bryan Czyzewski, Managing Director ...
Investor Sentiment: Predictability Wins in Health Tech & Services
This past Tuesday, June 10th, Gilmartin’s Managing Director, Ryan Halsted, hosted a webinar with TD Cowen’s Charles Rhyee (Senior Research Analyst, Healthcare Technology) and Ryan Langston (Senior...
Winning IR Strategies for Biotechs
Biotech investor relations strategies are being tested like never before, as companies today operate in one of the most challenging market environments in recent memory. From macroeconomic volatility ...
Healthcare Policy 2025 Outlook: Regulatory Insights from Washington’s First 100 Days
As the new administration reaches its early milestones, the healthcare policy 2025 outlook is top of mind for industry leaders. On March 26th, Stephen Jasper (Managing Director, Biotech) and Monique K...
MedTech Market Outlook 2025: IPOs, M&A Momentum, and Investor Revival
On February 6th, Lynn Lewis, Founder & CEO of Gilmartin Group, hosted a webinar with J.P. Morgan’s Annie Wernig and Benjamin Burdett. According to insights shared during the event, the MedTech m...
Gilmartin ESG Newsletter | January 2025
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
J.P. Morgan Healthcare Conference 2025 Insights: Sector Trends & Market Outlook
Last week, the J.P. Morgan Healthcare Conference once again gathered investors, analysts, bankers, and corporate teams in San Francisco to kick off the year with critical updates and discussions. Thes...
Understanding the SEC Form S-1 Filing Process for Going Public
As your company prepares to transition to public markets, understanding the SEC Form S-1 filing process is essential to ensure a smooth and successful IPO. This blog post highlights key considerations...
2025 Biotech Outlook: To JPM and Beyond
It’s that time of year again. With 2024 at a close, healthcare investors, analysts, bankers, and management teams are finalizing their JPM meeting wish lists and preparing to migrate to San Francisc...
Mastering Investor Day Presentations
The healthcare industry continues to expand as technological advancements drive innovation. In this competitive and ever-evolving landscape, how can you create an effective Investor Day presentation w...
Key Insights from Ceribell’s Initial Public Offering
Taking your company public is a significant milestone that offers exciting growth opportunities and meaningful access to capital. However, navigating the initial public offering (IPO) process can be c...
AI Governance 101: Best Practices to Ensure Compliance and Mitigate Risk
As artificial intelligence (AI) becomes more embedded in business strategies, its governance has emerged as a critical issue for companies seeking to leverage AI’s capabilities while managing regula...
Navigating the AI Landscape: Transparency and Accountability in Corporate Disclosures
As companies rush to integrate artificial intelligence (AI) into their products and corporate strategies, they are increasingly challenged to do so responsibly and transparently. Beyond the race for i...
Gilmartin ESG Newsletter | October 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Making Sense of the Fed’s Rate Cut by a 50bps vs. 25bps
What Happened? In its much-awaited first rate cut of the post-pandemic economic cycle, the FOMC cut the Fed Funds target rate by 50 bps to a range of 4.75%–5.00%. Prior to Wednesday, markets ha...
Gilmartin ESG Newsletter | September 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | August 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Impact of Past Presidential Elections on MedTech and Biotech Sectors
With the 2024 Election rapidly approaching, we took a look at the impact of the last three election cycles on the MedTech and Biotech industries. Given recent headlines, this 2024 election cycle ̵...
MedTech IPO and Capital Markets Perspectives
Gilmartin Group hosted 2 events in July focused on MedTech capital markets activity. Early in the month, our team co-sponsored a MedTech IPO Summit with Piper Sandler focused on IPO readiness an...
Gilmartin ESG Newsletter | July 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
The Current State and Outlook for Value-Based Care Across Healthcare Services and Tech
On July 11th, 2024, Gilmartin Group held a webinar discussing the current state and outlook for value-based care (VBC) across the healthcare services and tech space, featuring speakers Sean Dodge, Di...
Biotech Sector Trends: The Return of the PIPEs in 2024
Market volatility in the biotech sector is likely a product of macroeconomic headwinds The biotech capital markets came in hot to kickstart 2024 with 6 IPOs listed on NASDAQ or NYSE in the months of J...
State of the Union: Life Science Tools & Diagnostics
2024 started off with renewed optimism for the sector. Now, nearly six months into the year, it appears the set-up was not all that conservative for growth LS tools – with a number of companies post...
Biotech Trends & Outlook: A Conversation with Morgan Stanley
On June 12th, 2024, Gilmartin Group held a webinar with Matthew Harrison, Managing Director, Biotech Investment Banking at Morgan Stanley. The webinar covered the capital markets trends in the fi...
Gilmartin ESG Newsletter | June 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
13F Reports: Focus on the Why
Over the years, the U.S. Securities and Exchange Commission (SEC) has created and amended multiple reporting rules for most equity investor classes. For example, shareholders who acquire over 5% of th...
Gilmartin ESG Newsletter | May 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
NIRI Webinar Recap: Navigating Capital Markets and the Macroeconomic Landscape
On Thursday, March 21st, the National Investor Relations Institute (NIRI) held the webinar “Navigating Capital Markets and the Macroeconomic Landscape” with moderator Rose Sorensen (Partner, Snell...
Gilmartin ESG Newsletter | March 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
State of the Union: MedTech
Strong Fundamentals Driving Valuation RecoveryAs we close the book on 2023 and move deeper into 2024, MedTech fundamentals remain overwhelmingly positive. Procedure volumes, utilization, pricing trend...
MolDX Proteomics Testing and CMS’s Proposal to Downregulate IVD’s
On Tuesday, February 27th, Gilmartin Managing Director, David Deuchler, hosted a webinar with Hannah Mamuszka (Founder & CEO, Alva10), Ipsita Smolinski (Founder & Managing Director, Capitol St...
Gilmartin ESG Newsletter | February 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
2024 Biotech Outlook
This past Wednesday, January 31st, Gilmartin Group’s Managing Directors, Laurence Watts and Stephen Jasper hosted a webinar with Jefferies’ Michael Brinkman, Managing Director and Joint U.S. Head ...
Key Sector Takeaways Out of JPM 2024
Last week was a productive and efficient return to the J.P. Morgan Healthcare Conference held in San Francisco. The annual event reunited fervid participants and fostered meetings among investors, ana...
Gilmartin ESG Newsletter | January 2024
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | December 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Preparing for Climate Disclosure: Where Companies Can Start
Last week, Patrick Smith, Gilmartin’s Head of ESG Advisory and Green Project Technologies’ Founder and CEO Sam Stark had an in-depth conversation about the state of climate disclosure regulation t...
Gilmartin ESG Newsletter | November 9, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
GLP-1s and MedTech—How to Respond & What’s Ahead
The efficacy and availability of GLP-1s have caused a dramatic and unprecedented sell-off across the MedTech sector. Understanding management teams are well versed in many of the street’s views ...
Gilmartin ESG Newsletter | October 12, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | September 21, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | August 31, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | August 18, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Navigating SEC & FINRA Regulations in Healthcare
This past Tuesday, August 1st, Gilmartin Managing Directors, Laurence Watts and Stephen Jasper hosted a webinar with Latham & Watkins Partners Colleen Smith and John Sikora. The panel explored al...
Gilmartin ESG Newsletter | August 4, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | July 24, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | July 7, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Market Perspectives of Digital Health and Health Technology
This past Wednesday, June 21st, Gilmartin’s Managing Director, Ryan Halsted, hosted a webinar with BTIG’s David Larsen (Senior Research Analyst, Digital Healthcare/HCIT) and Marie Thibault (Senior...
Gilmartin ESG Newsletter | June 23, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Gilmartin ESG Newsletter | June 9, 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Counting Carbon: How Healthcare Companies Can Navigate the Emissions Reporting Landscape
Although climate change is one of the most widely discussed ESG and sustainability issues, disclosing climate-related information is not the first natural step for healthcare companies to take as they...
Analyst Interactions with Biotechs
This past Tuesday, May 2nd, Gilmartin Group hosted a webinar with TD Cowen’s Joseph Thome, PhD (Managing Director) and Tyler Van Buren (Managing Director), moderated by Gilmartin Managing Direct...
Macro-Environment Effects on Investment Decision-Making in Life Science Tools & Diagnostics
This past Wednesday, April 26th, Gilmartin Group hosted a webinar with three sell side analysts, Dan Arias (Managing Director, Stifel), Dan Brennan (Managing Director, Cowen) and Mark Massaro (Managin...
Navigating Today’s Liquidity Environment
On Tuesday, April 18th, Gilmartin hosted its inaugural Private Company Showcase, highlighting innovative private companies across various healthcare verticals. To kick off the day of presentations and...
Navigating IR: What Healthcare Executives Need to Know
Last Wednesday, April 5th, Gilmartin Founder & CEO, Lynn Lewis, moderated a panel at Biocom California’s CFO Breakfast & Networking Event in San Francisco. Joining for the discussion were Jo...
Webinar Recap | Medtech Spotlight 2023—What Matters From Here
Moderator: Marissa Bych, Principal, Gilmartin Group Guest Speakers: Travis Steed, Managing Director, Equity Research, Bank of America & Ryan Zimmerman, Managing Director, Equity Research, BTIG Ear...
Webinar Recap | ATM Usage by Biotechs at a Time of Depressed Valuation
Moderators: Laurence Watts, Stephen Jasper Participants from Cantor Fitzgerald: Steve Aldridge, Sameer Vasudev Gilmartin Group’s Managing Directors Laurence Watts and Stephen Jasper hosted a virtual...
The 2023 Gilmartin Reading List
Gilmartin Group prides ourselves on our “work hard, play hard” mentality and with the excitement of 2023 well underway, we’d like to shift our focus away from Investor Relations for just a momen...
Webinar Recap | The JPM “Post-Conference”: Medtech Insights and 2023 Expectations
Earlier this week, Gilmartin’s Founder & CEO Lynn Pieper Lewis hosted a webinar with J.P. Morgan’s Annie Wernig (Managing Director, Healthcare Investment Banking) and Benjamin Burdett (Man...
Gilmartin ESG Newsletter | January 2023
Welcome to the latest edition of Gilmartin Group’s ESG newsletter and our first release for 2023. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in t...
Key Sector Takeaways Out of JPM
Last week was a welcomed return to the in-person J.P. Morgan Healthcare Conference held in San Francisco each January. The annual event reunited fervid participants and fostered meetings among investo...
4 Things to Look for at JPM 2023
After a two year COVID-related hiatus, healthcare executives, investors, research analysts, bankers, and venture capitalists are once again headed back to San Francisco to meet with corporate manageme...
10 Tips for a Better J.P. Morgan Conference
JP Morgan 2023 is right around the corner. Readjusting to attending the conference in-person can be a bit daunting. To help spark your muscle memory and prepare you for a successful conference, we’v...
The Who & What of Investors | 2023 J.P. Morgan Conference & Beyond
Traveling to investor conferences can be time consuming and exhausting. While management teams are often provided with schedules from the conference host and investor biographies from Gilmartin, a nam...
Webinar Recap: Creative Financing & Investor Sentiment for Biotechs
WATCH WEBINAR REPLAY The Biotech team at Gilmartin recently hosted a webinar with BTIG on Creative Financing and Investor Sentiment for Biotechs. The webinar featured a Q&A session that was j...
5 Biotech Market Trends out of the Biocom California CFO Breakfast Panel
Biocom California recently hosted an in-person panel with three equity research analysts: Ritu Baral from Cowen, Laura Chico from Wedbush, and Josh Schimmer from Evercore. Moderated by NIRI San Diego ...
Webinar Recap: Fidelity Management & Research Virtual Buy-Side Engagement Panel
Fidelity recently hosted a webcast focused on engaging with investors. The panel featured a Q&A session with several portfolio managers and analysts who offered specific tips on what matters, what...
Keynote Recap: MedTech Financing in The Current Market
In the event you missed it, Gilmartin held its Inaugural Emerging Growth Company Showcase featuring a Keynote Panel on MedTech Financing in The Current Market that was joined by Morgan ...
Financial Forecasting During a Period of Macro-Economic Uncertainty
When investors evaluate investment opportunities, they look to management teams who accurately forecast and deliver results at or above guided levels. With macro-economic factors placing increasing pr...
Mid-Year 2022 Private Market Review (VC) and Fundraising Refresher
The past few years have been ones of immense strength and record activity for venture capital (VC). Following a monstrous and record-setting 2021, the first half of 2022 has been different of sorts. V...
Gilmartin ESG Newsletter | June 2022
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Common Questions Entering a Bear Market
Coming off the heels of a record breaking 2021, the first half of 2022 has shaped up to be less than ideal. With no one key driver in our current climate, factors such as eastern unrest, high inflatio...
The Return of In-Person Meetings
As COVID-19 became widespread in early 2020, global gatherings came to a complete standstill, emptying sports stadiums, airports, and restaurants. Investor events were no exception, with many investme...
The Un-stealthing Process for Early-Stage Private Companies
For early-stage private healthcare companies, the process of un-stealthing is thematically similar to the process of becoming a publicly traded company; namely, the company has to prepare for increase...
How to Leverage Your IR Calendar for Success
The IR calendar is a vital tool used by any investor relations professional. One of the most important aspects of IR is making sure that your management team is regularly in front of investors without...
How Public and Private Biotech Companies Should Utilize PR
Recently, the Gilmartin biotech team hosted a webinar with Berry and Company, discussing how public and private biotechnology companies should utilize public relations (PR). If you were unable to atte...
MedTech Research Coverage: Who Covers Whom?
While it may be easy to feel content with coverage from your group of supportive sell-side analysts, it is important to consider how this list will evolve throughout the lifespan of your company. For ...
Understanding Short Interest for Recent IPO’s
It is no secret that newly listed companies face a host of issues that many established public companies do not face. Whether it be a lack of executional credibility or liquidity issues caused by the ...
Gilmartin ESG Newsletter | April 2022
Welcome to the latest edition of Gilmartin Group’s ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, ...
Impacts of Labor Dynamics on Hospital Finances and the Healthcare Industry
Labor—salaries and wages for physicians, nurses, and other healthcare professionals—has historically represented a significant portion of hospitals’ operating expenses. For HCA Healthcare, one o...
Recap of Webinar: Demystifying ESG Reporting for Healthcare Companies
On March 17, 2022, the Gilmartin ESG team hosted a webinar with a panel of leaders from three healthcare companies that have integrated ESG into their decision-making and reporting processes. If you w...
How to Navigate Clinical Development Setbacks
Understanding the challenges biotech companies face when developing drugs is vital to assessing risk factors that might hinder a company’s clinical trial program. First, the probability of success i...
Recap of Webinar: Debt Financing for Emerging Biotechs
Recently, the Gilmartin biotech team hosted a webinar with Silicon Valley Bank (SVB), discussing debt financing for emerging biotech companies. If you were unable to attend, you can watch a replay of ...
Ins and Outs of “Down Rounds”
What is a “down round” and why would a company settle for these financing terms? To fully comprehend the circumstances that might lead to a down round, one first needs to grasp how private compani...
Gilmartin ESG Newsletter | February 2022
Welcome to the latest edition of Gilmartin Group’s ESG newsletter and our first update for 2022. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in th...
3 Advancements in Oncology for 2022
As we enter 2022, a new year, it is common to find ourselves full of hopefulness for the future. As we leave last year behind, we may also find ourselves reflecting on the past. Since 1933, cancer has...
Gilmartin ESG Newsletter | November 2021
Welcome to Gilmartin’s inaugural ESG newsletter. With a special focus on the healthcare sector, this newsletter sheds light on the latest trends in the rapidly evolving ESG space, covering developme...
The Rising Costs of National Healthcare
While there has been much focus across the U.S. recently on inflation throughout the economy, the healthcare industry has long captured the attention of the nation as costs have continued to rise stea...
The Makings of a Successful Crossover Round in Biotech
The crossover round has become a rite of passage to any biotech company intending to tap the public markets, whether it be to fund specific clinical programs that will lead to long-term value creation...
A New Legacy: The Shifting Investment Landscape of Family Offices
Family offices around the world have become increasingly active and sophisticated in their investment into innovations over the years. The growth of family offices and their broadened investment manda...
The SASB Standards: An Overview for the Healthcare Sector
With the rise of ESG integration across capital markets, investors are looking beyond traditional financial statements to understand how sustainability issues impact enterprise value. While companies ...
How the $3.5T Federal Spending Package May Impact the Healthcare Industry
After almost two years of near constant twists and turns through the COVID-era, the fiscal roller coaster ride isn’t over yet. As the House gears up to jockey over final details of the $1T spending ...
Dual Listings: Considerations and Processes to Ensure Success
It’s approaching dawn in New York. We’re keeping a watchful eye on trading, as our market in the East has opened, trying to get a sense for how the US market will react when it too opens for tradi...
A New Era of ESG – Environmental, Social, and Governance
2020 was a transformative year in recent history, and it also marked a pivotal year for ESG. Between the COVID-19 pandemic that upended the world, the swell of activism over social injustice, rising p...
Considerations of a SPAC: Part III – Takeaways from a Dozen Healthcare SPAC Processes
Given the prevalence of recent SPAC-sponsored public listings, the process of executing a successful SPAC combination may seem clearer than ever. Advantages of combining with an SPAC (Special Purpose ...
A Beginner’s Guide to Non-Deal Roadshows
Non-deal roadshows (NDRs) offer investors a comprehensive look at a company’s story that press releases, conference presentations, and other public documents cannot. Public and private companies ali...
Leveraging KOLs and PIs for Investor and Analyst Diligence
Before investing in or launching coverage on a company, investors and analysts will want to perform rigorous due diligence. The ability to leverage primary research can go a long way. Key opinion lead...
Recap of Webinar: “How to Engage with Sell Side Analysts”
Insights from a Candid Conversation with One of Wall Street’s Leading Biotech Analysts The Gilmartin biotech team recently held a webinar with Evercore biotech analyst Josh Schimmer on how to engage...
Maintaining Investor Trust and Shareholder Value Through a CEO Transition
When evaluating any company, investors look to the CEO for guidance, as CEOs are the bridge to the Street. As the face of the company, the CEO has to earn the trust of investors, customers, and employ...
Gilmartin Pizza Review
Earlier this year, we published our first ever Gilmartin Book Review to kick off 2021 on a lighter note. It was so well received that we decided to start our summer off on the right foot with a “Gil...
Tips & Tricks for a Smoother Earnings Report
Management teams are constantly juggling numerous tasks, and they often look for ways to improve and expedite processes. For public company management teams, reporting quarterly earnings is of critica...
Material Non-Public Information (MNPI) & Insider Trading – The Basics
Disseminating information to employees on the IPO is an important step in becoming a public company. As we have discussed before, there are certain topics that are critical to discuss with employees, ...
Gene Editing – The 21st Century Miracle
Gene editing? CRISPR? Everyone has heard the term CRISPR from mainstream media. But few can explain what it is or its significance for the future of human medicine. Hailed as a 21st century miracle, J...
Addressing Unfavorable or Undesired Analyst Coverage
Addressing Sell-Side Research Challenges: What to do When Your Company is Faced with Unfavorable or Inaccurate Analyst Coverage At the top of almost any IR to do list, and certainly one of the more im...
The Telehealth Upward Trend
The pandemic continues to accelerate the adoption of technology throughout the healthcare sector and investors are taking notice. Pre-COVID, many established companies and start-ups entered the digita...
How COVID-19 Continues to Affect Earnings
Twelve months ago, society as we knew it changed forever at the hands of the COVID-19 pandemic. As a result of this increased volatility and certain negative impact on health care systems and the glob...
Reinstating Guidance for 2021
Is it Time to Bring Back Guidance for 2021? When the COVID-19 pandemic started to affect the world in early 2020, nearly every business saw an immediate and meaningful impact on revenue. Public compan...
Disseminating Information to Employees on Your IPO
While transitioning to become a public company is a significant milestone in the corporate journey, moving forward toward this achievement, executives and employees face limitations around communicati...
Ignore the Noise
In his famous December 5, 1996 speech, former Federal Reserve Chairman Alan Greenspan stated, “But how do we know when irrational excitement has unduly escalated asset values, which then become ...
Activist Investors
There are many benefits to becoming a public company; however, the additional publicity does not come without risks. Suddenly, investors have access to buy and sell shares of your company on a day-to-...
Early 2021 Trends and 2020 in Blogs
Retail Momentum Market participant demographics are changing as new brokerage platforms like Robinhood, which offers convenient mobile apps and low commission trading, continue to attract the next gen...
The Purpose and Goals of Testing The Waters Meetings
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility...
Gilmartin’s 2021 Reading List
2020 brought a number of topics and trends to light within the healthcare sector, in which many of our peers have faced significant challenges throughout the year. We have addressed many of the topics...
Employee Sales on First Day of Trading
Should Employees be Allowed to Sell Shares on the First Day of Trading? Airbnb’s IPO Pop: Auction Transparency, Public Market Appetite & Equity Compensation The first day of trading, when a newl...
Board Diversity and Wall Street – An Emerging Priority
Over the past year, Wall Street has increased its focus on diversity and its implications for companies. This discussion is reflective of not only a broader national dialogue on social justice, but al...
Maximizing Presentations & Investor Meetings in the 2021 Virtual Conference World
As 2020 mercifully heads to the rearview mirror, it does appear that the virtual conference scene is likely here for at least the first half of 2021. Depending on the pacing of the vaccine rollouts, i...
Intro to Quarterly Financial Reporting
There are many decisions that must be made before every company’s earning call. Every company will have its own correct answer based on the past working experience and comfort level of the managemen...
What to Consider When Providing KPIs Post IPO
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility...
Director & Officer (D&O) Insurance for an IPO
Becoming a public company brings many benefits, including greater access to capital markets, additional publicity, and, of course, new cash to develop the business. However, an IPO also creates additi...
The Value Of Emergency INDs To Biotech Investors
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility...
Virtual Marketing Learnings
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility...
The SEC’s Proposed 13F Reform and its Implications on Public Issuers
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility...
Celebrating Your IPO During a Pandemic
The process of an initial public offering typically requires tons of work and can take months or even years to complete. The day a company begins trading on a national stock exchange is a great reason...
Understanding the Importance of the NASDAQ Biotech Index (NBI)
[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility...
Considerations if Your Company is Planning on Going Public Through a SPAC: Part 2
Positioning Your Company for Success Post SPAC or Reverse Merger When a company executes a reverse merger and/or becomes public via a Special Purpose Acquisition Company (SPAC) transaction, the newly ...
Considerations if Your Company is Planning on Going Public Through a SPAC: Part 1
Since January 2019, there have been about 15 US-listed SPAC IPOs compared to about 270 traditional IPOs. In our two-part series, we will explain the recent interest in SPACs and investor relations pro...
The Enduring Communications Playbook: How A Solid IR/PR Strategy Can Help Win Over Investors During Bull and Bear Markets
Strong investor relations and public relations strategies are core to building corporate visibility among investors of all sizes. Communications must ensure that key stakeholders are reached across a ...
How Management Teams Establish Credibility
How do management teams establish credibility and become well-regarded by investors and sell side analysts? Summary Well-regarded management teams are generally characterized by their ability to estab...
Revisiting Your IR Calendar
The COVID-19 pandemic has transformed the way we interact with everyone, including investors. Virtual meetings and conferences have become the new normal. While the personal, face-to-face conversation...
S-1 Business Section Drafting 101
Pre-Org Meeting IPO Prep: S-1 Drafting The S-1 is comprised of business and financial information designed to inform prospective investors and outline all material business risks. It offers an in-dept...
5 Things To Include In An IR Presentation
All companies, both public and private, will inevitably have to present their organization to investors. Though not every presentation is identical, there are some common topics that must be touched u...
What Makes an IR Website Best-In-Class?
Any company looking to attract market attention today should not underestimate the importance of a sophisticated corporate website with a high-quality investor relations section. We often tell clien...
Re-engaging with Investors After a Setback
Given the inherent scientific uncertainty in the drug development process, it is common for management teams to communicate equivocal or negative news to the investment community. Most seasoned biotec...
The ABCs of VC/PE: PART 2 – INVESTOR TARGETING
When a company initiates a fundraising process or contemplates a sale, it can be difficult to identify appropriate firms to target, structure diligence items internally, and adequately prepare for the...
IPO Timing Considerations
During these unprecedented times, one recurring question we hear from private companies is whether to go public now or wait till markets and society normalize. Since markets are by nature dynamic and ...
Secondary Offerings In The COVID World
With the COVID-19 pandemic continuing to overwhelm global economies and the uncertainty around the future and recovery timelines, many listed companies are recapitalizing through equity fundraising in...
Analyst Education during Your IPO Process – Part II: Financial Diligence Meeting
Initial public offerings (IPOs) are one of the most important milestones for many companies. During the IPO process, analysts are required to conduct formal diligence of the market opportunity, the un...
Analyst Education during Your IPO Process – Part I: Analyst Diligence Meeting
Initial public offerings (IPOs) are one of the most important milestones for many companies. During the IPO process, analysts are required to conduct formal diligence of the market opportunity, the un...
Could J.P. Morgan’s 2021 Healthcare Conference Be Cancelled?
J.P. Morgan’s Annual Healthcare Conference is widely regarded as an unmissable event for industry executives, bankers, analysts, and private and public investors. However, despite being the largest ...
How To Make The Most Of 13F Filing Information
Institutional investment managers with over $100 million in 13(f) securities that use the US mail or other means of interstate commerce are required to report their holdings as of the last day of each...
Shareholder Rights Plans
Following a company’s stock price being impacted by the COVID-19 pandemic, executive management teams should discuss any potential strategic implications on the company’s strategy with the board. ...
Navigating Investor Meetings During A Crisis
Many aspects of the business world have been affected by the COVID-19 pandemic, and plans for investor interactions in 2020 is no exception. Planning for scheduled investor interactions, such as non-d...
Virtual Annual Meetings
Annual meetings are a regulatory requirement for most public and private companies. While many retail investors may think a company’s annual shareholder meeting is like the extravaganza put together...
How is the Coronavirus Impacting Biotechs?
As the global number of confirmed COVID-19 cases soared past the one-million-mark last week, the United States has slowly climbed to the top of the list of most affected countries. While it is difficu...
Guidance Considerations for COVID-19
The everchanging news cycle has been accelerated with COVID-19 and the associated onset of daily, if not hourly, updates related to this global pandemic. Feeding into the news has been a set of dynami...
IR Considerations For Managing Your COVID-19 Response
In many ways, a crisis such as COVID-19 demands immediate action. Since January, and particularly over the past few weeks, we have seen a tremendous mobilization of government and private resources in...
The ABCs of VC/PE, Part 1
Before a company initiates a fundraising process or contemplates a sale, it can be difficult to identify appropriate firms to target, structure diligence items internally, and adequately prepare for t...
Environmental, Social & Governance (ESG) Part 2: How To Get Started
In part two of our series on Environmental, Social, and Governance (ESG), we will explore ways to jump-start your company’s entrance into this new level of disclosure. There has been a lot of insigh...
Environmental, Social & Governance (ESG) Part 1: Landscape & Scores
Environmental, Social, and Governance (ESG) considerations are becoming more relevant globally, and companies are now being evaluated on “non-financial” criteria alongside more traditional financi...
Five Ways Investor Relations Can Assist the Board of Directors
The investor relations team direct interactions with boards of directors are limited, but IR is a strong resource for the board in many situations. An integrated IR strategy with “boots on the groun...
Which is Better for Development-stage Biotechs: IR or PR?
A question I frequently get asked is this: As a development stage biotech, should I be engaging with a PR company or an IR company, and what is the difference? Let’s start with the latter first. Wha...
More Timing Considerations For Earnings Calls
In a 2017 blog titled Important Timing Considerations For Earnings Calls, we covered several things to keep in mind when scheduling quarterly earnings calls. In this blog we will review the quarterly ...
Preannouncing At The JPM Conference
“To pre-announce, or not to pre-announce, that is the question.” Next month marks the 38th year of the great pilgrimage to San Francisco. For five days every January, healthcare executives, invest...
Considerations for Visual Content in Investor Presentations
It goes without saying that a compelling investor presentation deck can be a resourceful tool for providing a company’s value proposition. The visual content of the deck, in particular, plays an imp...
Don’t Jump The Gun: Pre-IPO Considerations
With the right team in place, a compelling growth story, a comprehensive long-range plan, and a clear line of sight towards an IPO, executives become exceedingly proficient in marketing their company ...
Hiring an Outside Writer for Your S-1
One of the many decisions confronting a private company management when they begin contemplating accessing the public markets is how to write the S-1 document. The scope, complexity and legal requirem...
Financial Community Perception Surveys
Is it time to consider a financial community perception survey? At some point in a public company’s lifespan, it’s prudent to consider conducting a formal survey of the financial community. The pr...
Valuable Lessons from WeWork and Other Unicorns
Recent scandals among tech’s unicorns have turned investor attention to hypergiant funding and blitzscaling: Outcome Health faced an investor lawsuit regarding misleading claims; John Carreyou’s N...
IPO Lock-Ups and Early Releases
When a company is about to go public, early investors anticipate the stock rising after the IPO, but they must also endure a mandatory waiting period called the lock-up period. This period keeps pre-I...
A Guide to Rule 10b5-1 Plans
Insider trading restrictions can be a constant headache for companies and their executive officers. Executives who receive a significant portion of their compensation in the form of options, restricte...
Investor Relations Considerations for Biotechs Partnering with Big Pharma
Public and private investors in biotechnology stocks always look for the third-party validation of a biotech’s claims and technology. Multiple parties can provide such endorsements, including marque...
Setting Goals for the J.P. Morgan Healthcare Conference (2020)
The largest annual healthcare investment conference is quickly approaching. In the third week of 2020, from January 13—16, over 40,000 professionals will congregate in San Francisco to discuss healt...
Quiet Period: What It Means for Public and Private Companies
A quiet period is the period of time when company insiders are required to limit certain business-related communication with the public. During this time, communication is monitored and enforced by th...
Should All Companies Prepare Quarterly Earnings Slides?
As we have stated in multiple blogs, quarterly earnings calls are possibly the most important form of communication that companies have with the investment community. With the advent of Regulation Fai...
Insider Trading Basics
Despite insider trading being more commonly associated with illicit activities, legally, company insiders can buy and sell their stock. Legal insider trading activity is often tracked and analyzed by ...
How To Communicate A CEO Transition
Nearly every company, no matter the size, will eventually face a CEO transition. In fact, according to a study by Challenger, Gray & Christmas, the oldest executive outplacement firm in the US,C...
Managing Corporate Access as the Relationship between Investors and Investment Banks Evolves
For years, a mutually beneficial relationship existed between corporate management teams, investment banks and the buy-side regarding corporate access as represented by non-deal roadshows (NDRs) and c...
How To Prepare for a Short Attack
Short attacks have the potential to do significant and long-term damage to a public company’s valuation. Unlike the typical investor, a short seller seeks to gain from the decline in a company’s s...
IPO Pricing and Shares Offered Dynamics
Going public can be a daunting process, with multiple steps to take, decisions to make, and involvement from many constituents – management teams, boards of directors, investors, lawyers, bankers, a...
MiFID II Implications
One of the largest global regulatory packages in the past ten years became effective on January 3, 2018. The European Union’s Markets in Financial Instruments Directive, more commonly known as MiFID...
Financial Modeling for Biotechs
The average publicly listed biotech generates neither profit nor revenue. As such, so-called “quarterly earnings” announcements are typically non-events. Instead, management teams use quarterly re...
Earnings Video Conference Calls
Must see T.V. – Thoughts on using video broadcasting for earnings conference calls Earnings calls are arguably the most important form of communication that companies have with the investment commun...
Investor Targeting
Introduction Getting in front of investors who are active in your sector but may not be familiar with your company should be a top priority for public company management teams. It is especially import...
Pros & Cons of Professionally Taping Your Roadshow
An Initial Public Offering or IPO is the process of selling new or existing securities to the public for the first time. The process of “going public” consists of many steps, culminating in the pr...
IR Communications for Private Companies
A critical element in the foundation of any company is a solid investor relations (IR) strategy. Essential to this strategy is a structure that effectively drives IR communications that build and sust...
Follow-On Offerings
In previous blogs we have covered some of the basics of IPOs, the Importance of ATM Financing for Biotechs and Shelf Registrations. Today we look at a few basics of a marketed follow-on offering. Mark...
Engaging Hedge Funds
Hedge funds represent a substantial pool of potential capital to biotech management teams, but engaging with them can offer many challenges due to their varying structures and motivations. Underst...
Internal Forecasts, Guidance and Consensus Considerations
At the start of each earnings cycle, one of the first places we look to begin preparations for quarterly reporting is the external consensus numbers (what Wall Street expectations are) and our client�...
The Value of 13F Filings
Filed by institutional investment managers with at least $100 million in equity assets under management, SEC Form 13F is a quarterly report that must be completed no more than 45 days after the end of...
What is an ETF?
What Is An ETF? An ETF, or an exchange-traded fund, represents a portfolio of securities from traditional investments such as stocks or bonds to alternative assets like commodities or currencies, whic...
The Importance of ATM Financing for Biotechs
The story of a development-stage biotech company is one of almost continuous fund-raising. Why, you may ask? Well, in the absence of revenue, the expense of progressing a drug candidate through precli...
What Is Reg FD and How Does it Impact Me?
Regulation Fair Disclosure, better known as Reg FD, is a regulation on corporate communication promulgated by the SEC. The regulation limits public companies from disclosing material nonpublic infor...
Quarterly Earnings – Do We Really Need to Read The Script?
As we think about best practices for earnings and quarterly reporting, we focus on the message in its totality and how to best prepare. This means the press release, scripted remarks, Q&A preparat...
Investor Outreach: Keeping Up with a Changing Landscape
Marketing your company to investors can be extremely stressful and time consuming. Constant traveling to get your company in front of investors is not ideal, from both a budgetary and quality of life ...
Quarterly Earnings Calls: To Prerecord or Not Prerecord
The United States Securities and Exchange Commission (SEC) requires that public companies, whose securities trade on an exchange in the U.S., file quarterly and annual financial reports. According to ...
IPO Marketing, Pricing & Allocation Tips
You’ve spent the last 12 months preparing for your IPO and life as a public company, selected bankers, and have finally flipped your S-1 from confidential to public. But what’s next? As you pr...
Quarterly Earnings Calls: Key Components and Flow
Financial results announcements can have a meaningful impact on stock price and analysts’ sentiment, particularly for well-followed large caps and profile sector specific stocks. For publicly traded...
Environmental, Social, and Governance (ESG) and Its Relationship to Sustainable Investing
The importance of Environmental, Social and Governance, or ESG, is on the rise. But do you know how ESG relates to corporate social responsibility, or what it means for companies? In this article, we�...
Stock Delisting
Stock Delisting: A Summary In order for a company to be listed on a major stock exchange such as the New York Stock Exchange (NYSE) or the Nasdaq Stock Market, the company must meet and maintain sever...
Content of an Investor Relations Website
Many investors, both individual as well as institutional, use a company’s investor relations (IR) website as their source of primary information. An effective IR website helps generate interest and ...
Are Reverse Mergers A Good Way for Biotechs to Go Public?
In reality, some public companies fail. And in the world of biotechnology, failure is more frequent than in other industries where firms typically generate revenue and/or profits before seeking a stoc...
Volume 12 – December Recap
DECEMBER RECAP & BEYOND One of the worst Decembers in history. The sell-off in the equity markets continued in December, coupled with meaningfully greater volatility, resulting in exceptionally hi...
Volume 11 – November Recap
NOVEMBER RECAP & BEYOND Broad-based healthcare strength in November. The healthcare sector was up 6.8% in November, again outperforming the S&P which was up 1.8% in the month. Broad-based perf...
Getting to Know the Stock Exchanges
A big decision companies make after deciding to go public is which exchange they use to list their stock. The exchange acts as the market where stock is bought and sold by brokers and traders, and i...
2019 Medtech Outlook
While the final three months of 2018 wiped out much of the gains created in the overall market in the first three quarters of the year, the average large cap medtech stock outperformed the S&P 500...
Family Offices
Family offices. Suddenly, that term is showing up on a regular basis in the investment community as family offices are seen more and more regularly on company schedules for investor meetings at confer...
Preparing Your 2019 IR Calendar
‘Tis the season…yes, the one that comes around every year for preparing management’s calendar for the coming year. It may seem that pulling this together in one comprehensive, twelve-month calen...
Quarterly Earnings Calls: Planning & Preparation
Publicly-traded companies are required to report their financial results on a Form 10-Q no later than 45 days following the end of the quarter. Depending on the size and complexity of your company, yo...
Preparing for J.P. Morgan | Part II: Logistics and Packing
Happy Thanksgiving!! Last week, we wrote a piece on planning ahead for the annual J.P. Morgan Healthcare Conference in San Francisco. Unsurprisingly, it addressed investor relations related topics. Th...
Preparing for J.P. Morgan | Part I: Strategy
We have officially started planning for the annual J.P. Morgan Healthcare Conference in San Francisco which will run January 7-10, 2019. As with many of you, several of us at Gilmartin have been comin...
Volume 10 – October Recap
OCTOBER RECAP & BEYOND Broad market volatility. Broad market volatility punctuated October, with both the Dow and the S&P erasing gains for the year. Drivers of downward pressure were worry of...
Volume 9 – September Recap
SEPTEMBER RECAP & BEYOND Healthcare continues to outperform the broader market. Healthcare stocks continue to outperform the broader market gaining 2.8% vs. 0.4% for the S&P 500. Equipment &am...
Volume 8 – August Recap
AUGUST RECAP & BEYOND Healthcare outperforms the S&P 500 for the third month in a row. The Healthcare sector was up 4.2% in August, again outperforming the S&P 500, which gained 3.0%. Afte...
Volume 7 – July Recap
JULY RECAP & BEYOND Healthcare gains on strong start to Q2 earnings as tech giants weigh on broader S&P. The Healthcare sector was up 6.5% in July, outperforming the broader market (3.6%) and ...
Preparing for a Productive Investor Conference
Investor conferences provide a great opportunity for companies to increase their visibility among investors and Wall Street. Companies can use these events to attract new investors, deepen current inv...
Direct Listing IPO
Direct Public Offerings, or Direct Listings, gained attention in the first half of 2018 when Spotify bypassed the traditional underwritten IPO to list their shares on the New York Stock Exchange (NYSE...
Investor Presentation Best Practices
We have created a myriad of investor presentations and slides, sat through countless investor meetings and attended numerous conference presentations. As we think about preparing for the annual J.P. M...
Corporate Presentation or Fireside Chat?
The main objective for most companies that participate in investment bank conferences is increasing their exposure to current and potential new shareholders. With more than 70 investment bank healthca...
What is a Shelf Registration?
A shelf registration statement (or form S-3, in SEC terminology), is a flexible registration with the SEC that allows an issuer to essentially “pre-register securities” without a specified issuanc...
Communicating A Shortfall
All companies find a time when they need to deliver bad news – this could be on a myriad of topics: clinical trial data that falls short of expectations, litigation rulings that go the other way, pr...
The Long and The Short of Hedge Funds
Introduction to Hedge Funds Hedge Funds often have a bad reputation of being short sellers and/or frequent traders, due to short-term outlooks. While this may be true for some funds, it is important t...
Tips for Analyst and Investor Meetings
Things to Consider Before, During, and After Meetings with Wall Street A fundamental component of a proactive investor relations program includes regular outreach and meetings with sell-side analysts ...
Introduction to Dutch Auctions
A Dutch auction, also called a reverse auction, is the process of selling goods through an auctioneer who offers prices starting above the expected purchase price and then lowers prices until a buyer ...
Crisis Communication: Tips and Approaches
Nearly every organization will experience a crisis of some form within its lifetime. Lack of preparation for a crisis may result in an operational break down, confused and angry stakeholders, and an e...
What Is A Crossover Fund?
Crossover Funds: A Win-Win Scenario? A crossover fund is an investment fund that invests in both publicly-traded and privately-held companies. Crossover funds are designed to give investors the abilit...
Why Does Trading Volume Matter?
Trading volume is the number of a security’s shares traded during a given period of time. Trading volume indicates the overall activity of a stock and its momentum, and it is an important techni...
Introduction to Dark Pools
What are “Dark Pools”? “Dark pools” or “Dark pools of liquidity,” popularized by Michael Lewis’ 2014 book “Flash Boys,” are private trading platforms that provide a platform for the ...
The Role of Investor Relations in Passive, Quant & Hybrid Funds
Passively Managed Funds Usually, of the 25 holders in many companies, one or more are passively managed funds. Think of names like Dimensional Fund, Vanguard, and BNY Mellon. These institutions can ow...
Volume 6 – June Recap
JUNE RECAP & BEYOND The Healthcare sector was up 1.5% in June, outperforming the broader market (0.5%) and the Medtech universe (1.3%) for the first time in 2018 on the back of a broader shift to ...
What is a Greenshoe?
The Over-Allotment Option, or Greenshoe (named after the first company to use the instrument), is an often-misunderstood device that gives underwriters the means to stabilize a company’s stock for u...
The Importance of a Compelling Investor Deck
A storyteller is one of the most critical roles for a private company executive. Before milestones have been reached and revenue earned, companies must sell potential investors on the dream of what th...
Volume 5 – May Recap
MAY RECAP & BEYOND The S&P 500 (SPX) outperformed the Healthcare Sector for the first time in 2018, gaining 2.2% in the month, and now up 1.2% for the year. Healthcare posted flat returns for ...
Volume 4 – April Recap
APRIL RECAP & BEYOND Healthcare sector performance, which was up roughly 1% for the month of April and flat to down over the year (-0.5%) remains in-line, to slightly outperforming the broader mar...
Monitoring Short Sellers
A key discipline that investor relations professionals must actively develop is constantly monitoring investor sentiment, which is the overall attitude that investors have toward a particular market.�...
When Your S-1 Flips to Public from Confidential
Filing Form S-1 with the SEC Form S-1 is a filing with the Securities Exchange Commission (SEC) used by private companies planning to go public, and it is comprised of business and financial informati...
Does the Timing of Your Press Release Matter?
Press releases are an important component of any company’s investor relations program. We are often asked what, from an investor standpoint, is the best time to issue a press release? The truth is t...
Why Does a Private Company Need Investor Relations?
Many private companies ponder if and when they will need an investor relations program. While it may seem like a non-essential service for a private company, partnering with the right IR firm can be a...
Managing the Press Release Process
Press releases are an important component of any company’s investor relations program. They are a key method for companies to announce news to a variety of stakeholders. Creating and approving press...
What You Need to Know about the Russell Index Rebalancing
Every year, FTSE Russell creates a family of indexes, called the Russell Indexes, that measure the performance of broad segments of the US equity market. These indexes have become benchmarks for measu...
Understanding Regulation FD
Regulation Fair Disclosure (Reg FD) Regulation FD prohibits companies from disclosing material nonpublic information to select analysts, institutional investors and others without making widespread pu...
What type of content do investors look for on your IR website?
The Investor Relations portion of your website is a critical part of an investor’s learning experience surrounding your company. Both potential and current investors use your IR website as a quick r...
Managing Q&As: How to handle a difficult investor question
When planning ahead for your quarterly earnings call, it is critical to spend time focusing on the Q&A portion of your presentation. Prepping for questions that investors will likely ask allows yo...
How to Get the Most Out of Your Non-Deal Roadshow
The aim of a for-profit company, public or private, is to earn a profit through its operations. In a perfect world, stock returns of public, for-profit companies would be positively correlated with co...
Volume 3 – March Recap
MARCH RECAP & BEYOND The macro back-drop overshadowed sector driven effects in March with monetary policy, looming trade wars and tax reform contributing to the equity market’s continued volatil...
Tips for Planning a Successful Investor Day
In order to set your company apart in the competitive investment capital environment, it is vital to plan and execute an effective investor day. Investor days allow you to stay top of mind and have re...
How to Write a Shareholder Letter
A shareholder letter is an opportunity for a CEO to directly communicate with shareholders and to clearly lay out his or her vision for the company, align employees and other stakeholders around that ...
What to Consider in the 12 Months Prior to an IPO
The IPO process ramps up quickly. The 12 months before a company goes public is a period of increasing complexity that requires strong execution. We offer a framework of four broad areas to help you o...
The Relationship Between IR and PR
Perhaps the overlap between investor relations and public relations seems obvious because both roles are key communication functions within a company. But what about the relationship between the two f...
Volume 2 – February Recap
FEBRUARY RECAP & BEYOND We are off to an interesting start to the year! Healthcare stocks sold off in February in tandem with the S&P, but are still outperforming on a relative basis and remai...
How to Communicate a Management Transition to Your Investors
Management changes, while inevitable for most companies, can be stressful for both employees and investors. Communicating the change and plan of action well is essential to managing how employees and ...
What’s the consensus on guidance?
Should we give guidance? With what metrics? At what interval? These are questions management companies often struggle with when it comes to how they want to manage the street’s expectations. The ans...
Preparing for an IPO? Considerations for Choosing Investment Bank Partners
Executing an initial public offering is one of the most important milestones for many companies. It is vital that you do your homework when considering which investment banks you will use when you are...
Investment Banking and Industry Conferences: How to Maximize your Time and Get the Best Exposure
When thinking about your investor relations plan in the new year, it is critical to allot time for both industry and investment banking conferences. Staying in front of your current investors is criti...
Volume 1 – January Recap
JANUARY RECAP & BEYOND As we enter 2018 and on the heels of the J.P. Morgan Conference earlier in the month, January has been busy and productive marked by strong investor sentiment, healthcare se...
FAQs on How to Structure an Earnings Script
Collectively, we have written, edited and read hundreds – if not thousands – of earnings scripts. So, today we are highlighting some of our most frequently asked questions and sharing our best pra...
10 Ways to Improve the Quality of Your Webcasts and Extend Investor Reach
Webcasts of conference presentations and quarterly earnings calls have become a routine part of most public company IR programs. They offer a means for ensuring Reg FD compliance, extend the reach to ...
Takeaways from J.P. Morgan’s 2018 Healthcare Conference
The J.P. Morgan Healthcare Conference continues to be the largest healthcare investment symposium, bringing together global industry leaders, emerging growth companies and multiple constituents from t...
How Social Media Benefits Investor Relations
According to Merriam-Webster, social media are forms of electronic communication (such as websites for social networking and microblogging) through which users create online communities to share in...
What Your Company Needs to Know about Reverse Mergers
What is a Reverse Merger? A reverse merger, the most common alternative form of a public offering, allows a privately-held company to go public by acquiring a controlling interest in and merging with ...
Four Keys to Attracting and Maintaining Sell-Side Coverage
There are many factors that go into sell-side analysts’ decisions to pick up coverage on a stock. Some of the questions they will ask themselves include: How much trading volume does the stock have?...
Tips for Planning Your Investor Relations Strategy
We have spent considerable time determining best practices for planning annual investor relations (IR) activities. Our approach is holistic – we are strategic in how we determine annual goals for in...
The Best Practices for Large Cap Financial Reporting
We recently conducted a case study examining the best practices of quarterly financial reporting communications on twelve large cap, med tech companies, including Medtronic, Abbott Laboratories, Bosto...
How Many Sell-Side Analysts Should Your Company Have?
What’s the right number of analysts for your company? Each public company is different, and so are the analysts and investment banks that cover them. Analysts cover stocks for a host of reasons, inc...
Things to Consider During Blackout and Quiet Periods
Amongst the many rules and considerations that surround investor relations disclosure and trading practices, blackout and quiet periods are very important policies to implement and understand. Blackou...
Best Practices for Analyst Meetings
There are a variety of options for a company when it comes to analyst and investor events – full or half-day meetings on a standalone basis, formal meetings at industry tradeshows, or smaller roundt...
Preparing for Cyber Security and Data Breaches
Failing to plan is planning to fail. We attended a NIRI-hosted panel on cyber security and data breach in San Francisco, and we have been contemplating the implications for our client companies. The p...
Important Timing Considerations for Earnings Calls
Following the end of a quarter, depending on public float and certain exceptions following IPOs, the Securities and Exchange Commission (SEC) requires companies to file quarterly and annual results vi...
Uplisting to a National Exchange
Uplisting to a national exchange is an important goal for many small, over-the-counter (OTC) companies, but it is one that needs to be vetted thoroughly. There are several important considerations inc...
Attracting Analyst Coverage
The environment for sell-side analyst coverage has changed over time, due to a growing number of boutique banks and fewer bulge bracket firms. In addition, with consolidation in the sell-side industry...
Takeaways from J.P. Morgan’s 2017 Healthcare Conference
This year’s J.P. Morgan Healthcare Conference was similar to years past, bringing together global industry leaders, emerging growth companies, and multiple constituents from the investment community...